Rule 506(b); Investment Company Act Section 3(c)(1)
First filed
2022-03-25
Latest filing
2022-03-25
First sale
2021-08-13
Filings
1 Form D
People
Named in Item 3 of its latest Form D, filed 2022-03-25
Related persons
Name
Relationship
Clarification
SV Life Sciences Fund IV CF (GP), LLC
RelationshipExecutive Officer
ClarificationGeneral Partner of the Issuer
Kate Bingham
RelationshipExecutive Officer
Clarification—
Greg Madden
RelationshipExecutive Officer
Clarification—
Thomas Flynn
RelationshipExecutive Officer
Clarification—
Eugene Hill
RelationshipExecutive Officer
Clarification—
Paul LaViolette
RelationshipExecutive Officer
Clarification—
Michael Ross
RelationshipExecutive Officer
Clarification—
Houman Ashrafian
RelationshipExecutive Officer
Clarification—
Michael Balmuth
RelationshipExecutive Officer
Clarification—
History
2022-03-25Form D filed · 021-438954
The firm behind it, its other funds, and every Form D as filedSee plans
The firm and the filings behind SV Life Sciences Fund IV CF, L.P.
A fund's Form D states its target and what it has sold so far. The dashboard puts it beside the adviser's other funds from Form ADV, the startups linked to it, and every amendment as filed.
The adviser's Venture page: its Form ADV funds, assets and other Form D offerings
Where co-filings link it, the startups this fund backed
Every Form D and amendment as filed, with what each one stated
Everyone its filings name, linked to their other funds and companies
Part of the Venture plan — $140/mo at launch pricing ($350 list)